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Edited by Miguel De la RosaAbstract The solution structure of the catalytic domain of
MMP-20, a member of the matrix metalloproteinases family
not yet structurally characterized, complexed with N-Isobutyl-
N-(4-methoxyphenylsulfonyl)glycyl hydroxamic acid (NNGH),
is here reported and compared with other MMPs–NNGH
adducts. The backbone dynamic has been characterized as well.
We have found that, despite the same fold and very high overall
similarity, the present structure experiences speciﬁc structural
and dynamical similarities with some MMPs and diﬀerences
with others, around the catalytic cavity. The present solution
structure, not only contributes to ﬁll the gap of structural knowl-
edge on human MMPs, but also provides further information to
design more selective and eﬃcient inhibitors for a speciﬁc mem-
ber of this class of proteins.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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The knowledge of the structure of a target is a prerequisite to
design and optimize eﬃcient and selective drugs, particularly
when selectivity regards a family of targets.
Matrix metalloproteinases (MMPs) are a family of enzymes
belonging to the class of zinc- and calcium-dependent endo-
peptidases, involved in extracellular matrix degradation or
remodeling [1,2]. Overexpression or misregulation of MMPs
is related to several pathologies [3,4], and therefore their inhi-
bition is relevant in drug discovery [5].
MMPs are multidomains enzymes, constituted at least by a
prodomain and a catalytic domain. The latter contains two zin-
c(II) ions, one catalytic and the other, together with one to three
calcium(II) ions, with a structural role [6]. The substrate/inhib-
itor penetrates in a hydrophobic S1’ pocket of the catalytic do-
main whose size is variable within the MMPs family and aﬀects
the substrate/inhibitor speciﬁcity for a given MMP [5–7]. Hu-
man MMPs are 23 and a number of structures of the catalytic
domain complexed with a variety of inhibitors, is known [6–
10]. Still, there are members of the family poorly characterized*Corresponding author. Address: Magnetic Resonance Center, Uni-
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doi:10.1016/j.febslet.2007.08.069[11,12]. Enamelysin (MMP-20) is one among these; it is ex-
pressed exclusively in tooth-forming cells with an essential role
in normal dental enamel development [13]. MMP20-null mice
displays multiple enamel defects and mutations of the human
MMP20 gene have been associated with autosomal recessive
types of amelogenesis imperfecta [14], indicating that MMP-20
is a critical molecule for tooth enamel formation.
We report here the ﬁrst structure determination and mobility
studies of the catalytic domain of MMP-20 complexed with a
non-peptidic inhibitor (NNGH). The solution structure and
the dynamic data are then compared with those of other
MMPs complexed with the same inhibitor.2. Materials and methods
2.1. Sample preparation
The gene codifying the catalytic domain of MMP-20 (aa 113–272)
was cloned, expressed, and puriﬁed following an already reported pro-
tocol [8]. The MMP-20–NNGH adduct was prepared by adding the
NNGH during the ﬁnal concentration step. The NMR protein sample
concentration, determined by UV spectroscopy (extinction coeﬃcient
of 2.84 · 104 M1 cm1 at 280 nm), are 1.0–1.4 mM in Tris 20 mM,
pH 8, ZnCl2 0.1 mM, CaCl2 5 mM, NaCl 300 mM and acetohydroxa-
mic acid 0.3 M. Two equivalents of Ca2+ per protein were found from
inductively coupled plasma emission spectroscopy measurements.
The inhibition constant was determined, in terms of dissociation
constant Kd, evaluating the ability of NNGH to prevent hydrolysis
of the peptide Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, from the
initial hydrolysis reaction velocities at a ﬁxed concentration of enzyme
[15]. These measurements were performed in 50 mM HEPES buﬀer,
with 10 mM CaCl2, 0.05% Brij-35, 0.1 mM ZnCl2 (pH 7.0), with
non-saturating substrate concentrations.
2.2. NMR experiments and structure calculations of MMP-20–NNGH
complex
The NMR experiments performed on the MMP-20–NNGH
complex are reported in Table S1 of the Supplementary material, res-
onances assignment in Table S2 and deposited in the BioMagResBank.
The His coordination mode to the two zinc ions and the nature of the
coordinating nitrogens was determined through 1H–15N heteronuclear
experiment to detect 2J 1H–15N couplings between the imidazole
nitrogen and non-exchangeable imidazole protons [16]. Each of the
20 lowest target function conformers was energy-minimized in explicit
solvent with the program AMBER-8 [17]. Table S3 reports statistics on
restraint violations in the ﬁnal structure together with selected quality
parameters [18–20].
The R1 and R2 relaxation rates [21], and
1H–15N NOEs values [22]
were measured at 600 MHz (298 K) (Fig. S1). R2 was also measured
as a function of the refocusing time (sCPMG) in a Carr–Purcell–Mei-
boom–Gill (CPMG) sequence [23], which ranged between 450 and
1150 ls. The R1 and R2 relaxation rates and
1H–15N NOEs have
average values of 1.42 ± 0.16 s1, 14.0 ± 1.6 s1 and 0.80 ± 0.11,blished by Elsevier B.V. All rights reserved.
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was obtained from the R2/R1 ratio, consistent with the molecular
weight of the catalytic domain of MMP-20 being in the monomeric
state and with the value predicted by using HYDRONMR program
[24]. The relaxation data were analyzed with the program TENSOR2
[25] which follows the model-free approach of Lipari and Szabo [26]
(Fig. S2).
A 15N labeled MMP-20–NNGH sample was dialyzed against D2O
buﬀer to perform the H2O/D2O exchange experiments. Then, a
1H–15N HSQC spectrum of the sample was recorded after three days.3. Results and discussion
3.1. Solution structure of the MMP-20–NNGH complex
The catalytic domain of MMP-20 shares high sequence sim-
ilarity with other MMPs, from a minimum of 36% with MMP-
21 to a maximum of 60% with MMP-13 and MMP-2 [27].
Accordingly, the solution structure of the catalytic domain
of MMP-20–NNGH adduct shows the typical fold common
to all MMP catalytic domains (Fig. 1) [7], which consists of
three a-helices and a twisted ﬁve stranded b-sheet with a fur-
ther short two-stranded b-sheet located in the C-terminal part
of loop 7. The structure is overall stabilized by multiple hydro-
phobic interactions and by a network of H-bonds directly
identiﬁed through H2O/D2O exchange experiments. The sec-
ondary structure elements are well ordered (RMSD value with-
in the family of 0.41 ± 0.06 A˚) and only a few residues in the
loops (4, 5, 7 and 8) are slightly more disordered (Fig. S3).
Consistently, the order parameters S2, which monitor motions
in the ns–ps range are almost homogenous over the entire pro-
tein except for few residues located in loops (Fig. S2). How-
ever, internal dynamics is limited also in the loops and, in
particular, in the active-site loop (loop 8) which, on the con-
trary, is highly dynamic in several other MMPs previously
characterized, as MMP-1 [28], MMP-3 [10], MMP-12 [29]
and MMP-13 [30]. The amplitudes of the backbone motions
change from MMP3–NNGH with an average S2 value of
0.85 ± 0.05 [29], to MMP-20–NNGH with S2 of 0.94 ± 0.04.
This trend is also observed in the active-site region, where a
number of MMP-20 residues have S2 values higher than 0.90
and higher then in MMP-3 (Fig. S4). Some residues, all located
in loops, are involved in exchange processes occurring in theFig. 1. Solution structure of the catalytic domain of the MMP-20–
NNGH adduct. The zinc and calcium ions are in yellow and light blue,
respectively. The NNGH is in blue.ms–ls time range (Fig. S2). The occurrence of both conforma-
tional exchange processes and ns–ps motions for some residues
belonging to loop 5 matches the paucity of NOEs for this loop
(Fig. S3-A), and consequently is higher structural disorder (Fig
S3-B).
The two zinc and the two calcium ions have the same ligands
as found in other MMPs [27]. As suggested from sequence
analysis [27], the third calcium site is not conserved in
MMP-20 as experimentally conﬁrmed by inductively coupled
plasma emission.
The binding mode of the NNGH inhibitor, which is similar
to that reported for other MMPs [8,10,29], is well deﬁned by 61
intermolecular NOEs (Table S4). Its phenyl group penetrates
into the S1 0 pocket establishing hydrophobic contacts, with
residues located in four distinct regions: Val223, His226 and
Glu227 in helix a2, Ala190 and His191 in strand b4, Thr188,
Leu189 in loop 5 and His236, Leu243, Thr247 and Tyr248 in
loop 8. These regions deﬁne the S1 0 and S2 0 pockets of
MMP-20. The latter pocket is shallow and accommodates
the isobutyl side chain of NNGH, which is essentially solvent
exposed (Table S4). NNGH is also stabilized by H-bonds with
protein residues.
3.2. Comparison of the solution structure of MMP-20–NNGH
with other MMP–NNGH complexes
The structures of MMP-3-, MMP-10- and MMP-12–NNGH
adducts (2JNP, 1Q3A, 1RMZ) are very close to that of MMP-
20–NNGH, with an average RMSD of 1.7 A˚ (Fig. 2A). Struc-
tural variations, outside the uncertainty of the structures, are
located in loop regions, in particular in loops 5, 7 and 8. The
hydroxamate group and the pattern of H-bonds is also the
same for all four structures. Also sequence similarity with these
proteins is very high (Table S5). From the sequence analysis
(Fig. 2B) it appears that about 20 residues are the same or have
very similar chemical properties in MMP-3 and MMP-10 but
have a diﬀerent nature in both MMP-20 and MMP-12, being
identical or similar in these latter two proteins. These amino
acid variations could explain the similar inhibition constants
for NNGH of MMP-20 and MMP-12 on one side (17 nM
and 13 nM [29], respectively), with respect to those of MMP-
3 and MMP-10 on the other (130 nM [31] and 100 nM [8]).
Contacts within 5 A˚ between NNGH and these proteins in-
volve residues located in strand b4, helix a2, loops 5 and 8. The
major diﬀerences in the sequence among these four MMPs are
mainly located in the last region, where structural diﬀerences
are observed (Fig. 2B). They contribute to determine diﬀerent
shape and size of the S1’ cavity in MMP-20 and MMP-12 with
respect to MMP-10 and MMP-3, being in the latter two more
open than in MMP-20 and MMP-12. In MMP-10 and MMP-3
a Ser and a Thr, located in positions 249 and 251, respectively,
on loop 8 (MMP-20 numbering), are oriented towards loop 7
and solvent exposed, determining a more open conformation
of loop 8. On the contrary, in MMP-20 and MMP-12 the res-
idue in position 251 (Lys and Val, respectively) is pointing to-
ward loop 8 and extends into the S1 0 pocket (Fig. 2A), while a
one-residue gap is present in position 249 (Fig. 2B). The struc-
tural diﬀerences around the catalytic cavity between the two
pairs of proteins could play a role in determining their pair-
wise diﬀerent Kd values for NNGH.
Structural and mutagenesis studies indicated that residues in
the S1’ pocket, and particularly in position 222 (MMP-20
numbering) have a role in shaping this pocket [6]. A Leu is
Fig. 2. (A) Catalytic domain of the MMP-20–NNGH adduct (red) superimposed with MMP-12-, MMP-10- and MMP-3–NNGH. Relevant residues
deﬁning the S1 0 pocket are also shown in yellow, green and blue for MMP-12, MMP-10 and MMP-3, respectively. (B) Sequence alignment of MMP-
20, MMP-12, MMP-10 and MMP-3 proteins. The residues coordinating the catalytic and the structural zinc ions are in yellow boxes, those binding
the calcium ions are in gray boxes. Residues in position 249 and 251 (MMP-20 numbering) are in cyan boxes. Residues having similar chemical
properties in MMP-10 and MMP-3 but diﬀerent in both MMP-20 and MMP-12 are colored in red.
Y. Arendt et al. / FEBS Letters 581 (2007) 4723–4726 4725usually present (Fig. 2B), or less often an Arg residue. MMP-
20 is the only one to have a Thr in this position. The side chain
of this residue is oriented towards the methoxy group of the
inhibitor in all the MMP–NNGH available structures forming
protein-inhibitor/substrate interactions. Also this residue could
be therefore important in regulating the MMP-20 substrate
speciﬁcity considering the diﬀerent steric hindrance between
a Leu and a Thr.
4. Concluding remarks
The structure of another member of the MMPs family is
here reported for the ﬁrst time, thus contributing to ﬁll the
gap of structural knowledge on this important class of drug
targets. Despite the overall similarity in structure within the
proteins of the family, knowledge of the subtle structural dif-ferences among MMPs could contribute to the design of more
eﬃcient and selective inhibitors within MMPs family [32,33].
The relevance of selectivity is increased by the need to avoid
the inhibition of MMP-20, since deletion of MMP-20 gene
or its mutation are associated to pathologic states [14].
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The atomic coordinates and structural restraints for MMP-
20–NNGH have been deposited in Protein Data Bank and
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tary data associated with this article can be found, in the online
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